Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. The trade was a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Trading Up 1.7 %

Shares of CNTA stock traded up $0.30 during trading hours on Wednesday, reaching $17.60. 510,281 shares of the stock were exchanged, compared to its average volume of 416,579. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.51 and a beta of 1.47. Centessa Pharmaceuticals plc has a 12-month low of $5.58 and a 12-month high of $18.74. The company’s 50-day moving average price is $16.13 and its 200-day moving average price is $12.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. Franklin Resources Inc. boosted its stake in shares of Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after purchasing an additional 1,145,823 shares during the period. Geode Capital Management LLC lifted its holdings in Centessa Pharmaceuticals by 68.7% during the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock valued at $905,000 after buying an additional 23,058 shares in the last quarter. Jane Street Group LLC purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at about $2,834,000. Wellington Management Group LLP bought a new position in Centessa Pharmaceuticals in the 3rd quarter worth about $1,609,000. Finally, State Street Corp purchased a new position in shares of Centessa Pharmaceuticals during the third quarter worth approximately $777,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Oppenheimer reiterated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. BMO Capital Markets increased their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Guggenheim boosted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target for the company. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.